JAZZ Q2 2021 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$752M+33.7% YoY

Gross Profit

$633M84.1% margin

Operating Income

-$70M-9.3% margin

Net Income

-$363M-48.3% margin

EPS (Diluted)

$-6.11

QoQ Revenue Growth

+23.7%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$35M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$13.2B

Total Liabilities

$9.1B

Stockholders' Equity

$4.1B

Cash & Equivalents

$891M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$752M	$562M	+33.7%
Gross Profit	$633M	$534M	+18.4%
Operating Income	-$70M	$198M	-135.1%
Net Income	-$363M	$115M	-416.5%

Revenue Segments

Xyrem

$334M45%

Xywav

$124M17%

Epidiolex/Epidyolex

$109M15%

Zepzelca

$56M7%

Defitelio/Defibrotide

$48M6%

Vyxeos

$31M4%

Erwinaze And Erwinase

$28M4%

Sunosi

$12M2%

Other Products

$3M0%

Sativex

$2M0%

Geographic Segments

UNITED STATES

$691M92%

Europe

$47M6%

Other Countries

$14M2%